Blood's Drug-Free Heat Patch Wins a Shelf at AEON Wellness and Guardian

For many, the first line of defense against menstrual pain is a pharmaceutical one. Blood, a Singapore-based femtech startup founded in 2014, is betting that a significant portion of the market wants a different option. The company’s foundational product, MenstruHeat, is a drug-free adhesive heat patch, a physical intervention aimed at dysmenorrhea, the clinical term for painful periods [Femtech Insider, retrieved 2024]. This focus on natural, non-pharmacological solutions forms the core of a decade-long effort to address both product efficacy and the persistent cultural stigma surrounding menstruation in Southeast Asia.

Blood’s journey is a patient one, reflecting the slow but steady work of shifting consumer habits and retail conversations. The company, founded by husband-and-wife team Peck Ying Tan and Caleb Leow, has raised a reported $2.85 million across several funding rounds since 2018, with DSG Consumer Partners leading a $1.59 million Series A1 extension in 2023 [PitchBook, retrieved 2024]. That capital has funded a product line expansion into items like corn-based sanitary pads and, critically, a move from direct-to-consumer online sales into physical retail. The placement of its products on shelves at major pharmacy chains AEON Wellness and Guardian represents a tangible milestone, bringing cycle care out of the digital cart and into the mainstream consumer aisle.

A wedge of natural efficacy and cultural change

Blood’s positioning attempts to solve two problems at once. The first is straightforward: providing effective, accessible relief for menstrual discomfort. The second is more nuanced, aiming to “challenge the societal taboos associated with menstruation” in its regional market [Femtech Insider, retrieved 2024]. Its product philosophy rejects a purely pharmaceutical pathway, instead emphasizing natural materials and drug-free mechanisms. This creates a clear, if niche, differentiation in a femtech and wellness landscape often crowded with supplement brands and digital tracking apps. For consumers wary of medication or seeking complementary care, it offers a defined alternative.

The company’s evolution from a single heat patch to a broader “cycle care” brand suggests an ambition to own more of the menstrual health journey. However, without a digital or diagnostic component,a common feature in modern femtech,its expansion remains firmly in the realm of physical consumer goods. The success of this model hinges on continuous product innovation, brand loyalty, and the scalability of retail distribution.

The team and the ten-year build

Leadership stability is a notable asset. Co-founders Peck Ying Tan and Caleb Leow have been steering the company since its inception, a longevity that provides continuity in a long-term market-building effort [TechMae, retrieved 2024]. The team has been bolstered with commercial roles, including a Head of Sales and a Strategic Ops Lead, indicating a focus on scaling operations [Prospeo, retrieved 2024]. The company has also brought on a consultant to build its brand in Indonesia, signaling a deliberate geographic expansion strategy within Southeast Asia.

This measured growth is reflected in the company’s funding history, detailed below.

2018 Series A | 0.76 | M USD
2020 Series A1 | 0.502 | M USD
2023 Series A1 | 1.59 | M USD

Navigating a crowded wellness landscape

The competitive field for mindshare in women’s health is dense. In Southeast Asia, Blood faces other regional players like theAsianparent and Moom Health, which often blend content, community, and commerce. The broader global femtech wave has raised consumer expectations, with many solutions incorporating personalized data, telehealth, or subscription models. Blood’s purely physical product suite exists adjacent to this trend, not within it. The primary risk is that its natural, drug-free wedge may be perceived as limited, especially for individuals with severe menstrual symptoms like those from endometriosis, where clinical intervention is often necessary.

The company’s most plausible answer is to deepen its authority within its chosen lane. By owning the “natural cycle care” category through product excellence and trusted retail partnerships, it can build a defensible, if specialized, business. Its success will depend on proving that a significant customer segment prioritizes this approach over integrated digital-physical solutions or conventional medicine.

The standard of care for period pain

For the patient population dealing with primary dysmenorrhea, the standard of care today often begins with over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. For more severe cases, hormonal contraceptives may be prescribed to manage symptoms. While effective for many, this pharmaceutical pathway is not preferred by all, due to side effects, personal health philosophies, or lack of access. This leaves a gap for non-pharmacological interventions, which range from heating pads and dietary changes to acupuncture and physical therapy. Blood’s MenstruHeat patch and related products aim to serve this gap, offering a discreet, drug-free option that can be used alone or alongside other treatments. The clinical question, unanswered without peer-reviewed study, is the comparative efficacy of such a modality against established first-line options.

What to watch in the next twelve months

The immediate trajectory for Blood will be defined by retail execution and product iteration. Key milestones to watch include the performance of its in-store placements at AEON Wellness and Guardian, which serve as a live test of mainstream demand. Further expansion into other regional retail chains or markets like Indonesia would signal successful traction. The company may also seek to extend its product line with new natural solutions, potentially venturing into adjacent areas of cycle-linked wellness. Given its last funding round was in early 2023, another capital raise to fuel this expansion could materialize in the near future.

Sources

1. [Femtech Insider, retrieved 2024] Blood company profile and mission | https://femtechinsider.com/
2. [TechMae, retrieved 2024] Profile on Blood's founders and focus | https://techmae.com/
3. [PitchBook, retrieved 2024] Blood funding round details | https://pitchbook.com/
4. [Prospeo, retrieved 2024] Blood team roles and structure | https://prospeo.io/
5. [6] Development of corn sanitary pads | Source note 6
6. [8] Product availability in AEON Wellness and Guardian | Source note 8